Strategies for translating proteomics discoveries into drug discovery for dementia
Aditi Halder1
Eleanor Drummond2
1.School of Medical Sciences and Brain & Mind Center,University of Sydney,NSW,Sydney,Australia;Department of Aged Care,Prince of Wales Hospital,Sydney,NSW,Australia2.School of Medical Sciences and Brain & Mind Center,University of Sydney,NSW,Sydney,Australia
摘要：Tauopathies,diseases characterized by neuropathological aggregates of tau including Alzheimer's disease and subtypes of frontotemporal dementia,make up the vast majority of dementia cases.Although there have been recent developments in tauopathy biomarkers and disease-modifying treatments,ongoing progress is required to ensure these are effective,economical,and accessible for the globally ageing population.As such,continued identification of new potential drug targets and biomarkers is critical."Big data"studies,such as proteomics,can generate information on thousands of possible new targets for dementia diagnostics and therapeutics,but currently remain underutilized due to the lack of a clear process by which targets are selected for future drug development.In this review,we discuss current tauopathy biomarkers and therapeutics,and highlight areas in need of improvement,particularly when addressing the needs of frail,comorbid and cognitively impaired populations.We highlight biomarkers which have been developed from proteomic data,and outline possible future directions in this field.We propose new criteria by which potential targets in proteomics studies can be objectively ranked as favorable for drug development,and demonstrate its application to our group's recent tau interactome dataset as an example.
机标关键词：proteomicsstrategiesdiscoverydementiadiscoveriesdrugintotranslating
论文发表日期：2024-01-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：8( 132-139 )
英文信息